Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation

Nicole Haverland, Gwénaël Pottiez, Jayme Wiederin, Pawel Ciborowski

Abstract

Background: Proteomic-based discovery of biomarkers for disease has recently come under scrutiny for a variety of issues; one prominent issue is the lack of orthogonal validation for biomarkers following discovery. Validation by ELISA or Western blot requires the use of antibodies, which for many potential biomarkers are under-characterized and may lead to misleading or inconclusive results. Gelsolin is one such biomarker candidate in HIV-associated neurocognitive disorders.

Methods: Samples from human (plasma and CSF), monkey (plasma), monocyte-derived macrophage (supernatants), and commercial gelsolin (recombinant and purified) were quantitated using Western blot assay and a variety of anti-gelsolin antibodies. Plasma and CSF was used for immunoaffinity purification of gelsolin which was identified in eight bands by tandem mass spectrometry.

Results: Immunoreactivity of gelsolin within samples and between antibodies varied greatly. In several instances, multiple bands were identified (corresponding to different gelsolin forms) by one antibody, but not identified by another. Moreover, in some instances immunoreactivity depended on the source of gelsolin, e.g. plasma or CSF. Additionally, some smaller forms of gelsolin were identified by mass spectrometry but not by any antibody. Recombinant gelsolin was used as reference sample.

Conclusions: Orthogonal validation using specific monoclonal or polyclonal antibodies may reject biomarker candidates from further studies based on misleading or even false quantitation of those proteins, which circulate in various forms in body fluids.
the validation of potential biomarkers. For example, orthogonal validation using Western blot or ELISA requires the use of antibodies; some of which are not well characterized and when used, may result in misleading or skewed data.

Proteomic studies from our laboratory have shown that gelsolin is differentially expressed in the plasma and Cerebrospinal Fluid (CSF) of Human Immunodeficiency Virus (HIV)-infected individuals with and without dementia [17–19]. Likewise, gelsolin circulating in the plasma of monkeys infected with simian immunodeficiency virus (SIV) is also differentially expressed between pre-infection, acute and chronic infection [19]. We have also found that monocyte derived macrophage (MDM) activated by HIV infection in vitro produce and secrete gelsolin (Ciborowski, P.; Kraft-Terry, S. both unpublished). Taking this together, we postulated that if gelsolin is validated, it may become a candidate as a diagnostic biomarker and be justified to move to experiments using larger cohorts of patients. However, validation of the differential expression of gelsolin in body fluids occurred to be a challenging task, as quantitative Western blot did not confirm differential expression unambiguously. As further studies indicated this was caused by two major reasons. First, high variability in the immunoreactivity of commercially available antibodies and the variability in recognition of gelsolin originating from CSF or plasma resulted in ambiguity. Second, immunoaffinity purification of gelsolin followed by MS/MS revealed that although the gelsolin circulating in the plasma and CSF was the secreted form of gelsolin (plasma gelsolin; pGSN), several other forms in addition to the full-length molecule (86kDa) were also in circulation ranging in molecular weight from 10 kDa to 188 kDa [20]. Based on these prior studies and observations, this study focused on problems with validation of gelsolin using antibody based orthogonal assays.

Materials and methods

Samples and Sample Processing

Four sets of human and non-human primate samples were used throughout this project: two sets of human plasma, one set of human CSF, and one set of non-human primate plasma. Human plasma and CSF samples were previously obtained from the National NeuroAIDS Tissue Consortium (NNTC, http://www.nntc.org) under request #R101. The samples were classified based only on neurocognitive status (non-demented [ND], sub-symptomatic, or HIV-associated dementia [HAD]); no other criteria (age, race, gender, T-cell count, viral load, etc.) were applied for sample selection. Two additional sample sets were obtained: human plasma from the California NeuroAIDS Tissue Network (CNTN) at the University of California San Diego, CA (from Drs. I. Grant, R. Ellis, S. Letendre) and Rhesus macaques plasma samples were obtained from Dr. Robert M Donahoe, University of Utah, UT [21]. The UNMC Institutional Review Board approved the use of the human clinical samples (#196-05-EX).

Prior to any type of sample processing, proteases and virus were neutralized using a solution of 10 μL - 10% Triton X-100 and 50 μL - 20X cocktail of protease inhibitors (Sigma-Aldrich; St. Louis, MO) per mL of sample as described previously in Wiederin et al. [19].

Each CSF sample was split into separate parts: one was used for immunodepletion and another for immunoaffinity purification. Immunodepletion was performed as described in Rozek et al. [18] using the Multiple Affinity Removal Spin Cartridges Hu-6 (Agilent; Santa Clara, CA). Plasma samples from CNTN, San Diego were immunodepleted as described in Pottiez et al. [20] using the Seppro® IgY 14 LC10 Column (Sigma-Aldrich). Rhesus macaques plasma samples were immunodepleted as described in Wiederin et al. [19] using the ProteomeLab IgY-12 High Capacity Proteome Partitioning Kit (Beckman Coulter; Fullerton, CA). Following immunodepletion, all samples were stored at -80°C.

Non-immunodepleted plasma and CSF samples from NNCTC were pooled based on source and neurocognitive status immediately before immunoaffinity purification of gelsolin. A 1 mL capacity HiTrap NHS-activated HP affinity column (GE Life Sciences; Pittsburg, PA) was used for immunoaffinity purification and was performed as described in Pottiez et al. [20]. Protein quantity for each fraction was analyzed using a NanoDrop 2000 (ThermoScientific, Inc., Waltham, MA) and fractions containing protein were pooled, dialyzed in MilliQ water and stored at -80°C.

In addition to plasma and CSF samples, human monocytes were isolated and cultured for this project. Monocytes were isolated by leukophoresis from donors whom were HIV-1, -2, and hepatitis seronegative as described in Gendelman et al. [22]. These monocytes were cultured and differentiated as described in Ciborowski et al. [23] and infection with HIV-1 ADA (multiplicity of infection: 0.1) occurred 7 days post-plating. Cell supernatants were collected from both HIV-infected and non-infected control cells at day 3 post-infection.

Commercial Gelsolin and Anti-Human Gelsolin (hGSN) Antibodies

Human recombinant plasma gelsolin protein was obtained from Cytoskeleton, Inc. (Denver, CO). Human plasma gelsolin protein was obtained from Sigma-Aldrich.

Antibodies used throughout this study included mouse anti-human gelsolin (hGSN) monoclonal antibody (mAb) (BD Biosciences; San Jose, CA), goat anti-hGSN C-20 polyclonal antibody (pAb) (Santa Cruz Biotechnology, Inc.; Santa Cruz, CA), and rabbit anti-hGSN pAb.
(Abcam; Cambridge, MA). The appropriate horseradish peroxidase (HRP) conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, Inc; West Grove, PA) were used for Western blot. A total of 1 mg goat anti-hGSN pAb antibody (Santa Cruz Biotechnology) was purified by protein-G affinity chromatography (Pierce; Rockford, IL) following manufacturer’s protocol and used for immunoaffinity purification of samples.

**One dimensional gel electrophoresis (1DE) and in-gel tryptic digest**

Samples were desiccated using a SpeedVac (ThermoScientific) and resolubilized in 20 μL NuPAGE (Invitrogen; Carlsbad, CA) sample buffer with reducing agent prior to heating and gel loading. 1DE was performed using NuPAGE® Novex® precast 4-12% Bis-Tris Gels (Invitrogen) under reducing conditions. The gel was run for 90 minutes at 100 V. Human immunoaffinity purified plasma and CSF derived gelsolin gels were fixed and stained with brilliant-blue G-colloidal concentrate (Sigma-Aldrich). Remaining samples were used for Western blot.

Bands from plasma immunoaffinity purified gelsolin samples were excised using a razor blade, destained, and digested in-gel using modified trypsin. Destaining consisted of two 30-minute washes using first 200 μL of 20 mM NH₄ HCO₃/50% acetonitrile (ACN), then 200 μL of 100% ACN. After destaining, the gel slices were desiccated and treated with 0.1% TFA. Reverse-phase C18 Zip-Tips® (Millipore; Billerica, MA) were used to purify extracted peptides following manufacturer’s protocol.

**Identification by LC/ESI-MS/MS**

Mass spectrometric analysis was carried out using an LC/ESI-MS/MS system in a nanospray configuration using a microcapillary reverse phase RP-C18 column (New Objectives; Woburn, MA). An LCQ-Deca XP Plus ion trap mass spectrometer (ThermoScientific, Inc.) was used to perform tandem mass spectrometry. Spectra were searched and proteins were identified following procedures stated in Pottiez et al. [20].

**Western blot**

Following electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Bio-Rad; Hercules, CA) for immunodetection as previously described in Ciborowski et al. [24]. Manufacturer’s recommendations were followed for each antibodies used in the detection of gelsolin in samples; each primary (anti-hGSN) antibody was used at a 1:1000 dilution in phosphate buffered saline with 0.02% Tween-20 (PBST) and 10% (w/v) skim milk; each secondary antibody was used at a 1:20,000 dilution.

**ExPASy Compute pi/Mw tool**

Based on the sequences identified using LC/ESI-MS/MS, the theoretical molecular weight was calculated using the ExPASy Compute pi/Mw tool http://www.Expasy.org. For each band, the peptides from the most N-terminal and C-terminal regions were selected as the form endpoints. Using the FASTA sequence for secreted pGSN, all amino acids between those N-terminal and C-terminal amino acids were identified and this shortened sequence was used to generate a theoretical molecular weight.

**Results**

Previously published MS-based proteomic studies have shown that plasma gelsolin (pGSN) is differentially expressed in HIV infected humans, SIV infected monkeys and *in vitro* HIV infected MDM [18-20,23]. Prior to conducting further studies using larger cohorts of samples from patients, we attempted to validate its expression using a smaller number of samples. Our validation effort using quantitative Western blot analysis gave ambiguous results and indicated that differences in validation strongly depend on which antibody was used. Therefore, the initial goal of our study was to select an anti-gelsolin antibody that when used for quantitative Western blot analysis would most closely reflect the results of proteomic profiling.

**Specificity of anti-gelsolin antibodies**

Subsequent experiments brought to light new information concerning our previous results of Western blot validations [25] in which we observed a single band corresponding to the full-length gelsolin molecule. Concurrent experiments of immunoaffinity purification from the same samples showed multiple forms of gelsolin. This discrepancy prompted us to further explore the specificity of anti-hGSN antibodies to explain if Western blot validation of proteomic profiling might be biased and do not reflect real levels of intact and processed forms of gelsolin. From more than 20 commercially available anti-hGSN antibodies, we selected three: mouse monoclonal, goat polyclonal and rabbit polyclonal; all were raised against an epitope from the C-terminal portion of gelsolin. A sheep polyclonal anti-hGSN antibody was also tested, but results could not be obtained due to high background (data not shown). Figure 1A is a schematic diagram of the gelsolin molecule along with the location of the epitope corresponding to each antibody. Figure 1B summarizes the specificity of those three anti-hGSN antibodies used for Western blot assay against the
Figure 1 Immunorecognition of hGSN by three antibodies in Western blot assay. (A) The location of epitope specific to the mouse, goat and rabbit anti-hGSN antibodies are provided in reference to the full-length pGSN. Numbers above each epitope correspond to the amino acid sequence from the full-length (with signal sequence intact) pGSN containing peptides used as antigens. (B) Summary of Western blot analyses revealing that immunoreactivity of pGSN depends on not only antibodies but also source of antigen. Total protein loaded per source per lane: 25 μg of human plasma from HIV-infected individuals, 10 μg of human CSF from HIV-infected individuals, 20 μg of cell supernate from both HIV-infected and non-infected cells, 25 μg of monkey plasma from pre- and 10 days post-infection of rhesus macaques with SIV, and 2 μg each of commercially available gelsolin. Membranes from each source were probed with mouse anti-hGSN, goat anti-hGSN, and rabbit anti-hGSN (all 1:1000) and corresponding HRP-conjugated secondary antibodies (1:20,000) diluted in PBS supplemented with 10% Tween-20 and 10% (w/v) skim milk.
gelsolin found various samples. It was unexpected that that monoclonal antibody raised to a synthetic peptide (located in the C-terminal end of gelsolin) reacted only with a single band of approximately 86 kDa, corresponding to the full length and intact gelsolin molecule. This indicated the conformational dependence of the antibody; moreover, it suggested that the conformation of the entire molecule - not only its C-terminal portion - is necessary for its immunoreactivity. Furthermore, Western blot analysis using either goat or rabbit pAb recognized additional forms of gelsolin with both larger and smaller molecular weights. It is likely that the smaller molecular weight forms are truncated forms of gelsolin in the full-length molecule based on trends observed by LC/ESI-MS/MS (Table 1). Further analysis using LC/ESI-MS/MS revealed that the larger molecular weight form (Figure 2A, asterisked band) contains fibronectin, which co-immunopurified with gelsolin; this comes as no surprise as it is well known that fibronectin binds gelsolin [26].

It was most unexpected that goat and rabbit pAb showed such great differences in immunoreactivity within samples. For example, goat pAb reacted weakly with only one form of gelsolin in the CSF whereas rabbit pAb recognized strongly two forms of gelsolin in that same sample. None of these antibodies recognized a form of gelsolin in any sample with a molecular weight lower than 45 kDa with the exception of goat pAb against commercially available human pGSN (Sigma Aldrich), which was able to recognize an additional band with a molecular weight of less than 38 kDa. In addition to the lower molecular weight forms, there were several samples in which higher molecular weight forms were detected; goat anti-hGSN pAb was able to detect these higher molecular weight forms in both human plasma and commercial gelsolin samples. Protein purification and concentration can often cause proteins to aggregate, which is a potential explanation for these higher molecular weight bands. These higher molecular weight bands warranted further investigation and using LC/ESI-MS/MS on bands excised from recombinant gelsolin, we were able to positively identify only gelsolin.

**Imunoaffinity purification of gelsolin from plasma or CSF**

1DE of immunoaffinity purified CSF and plasma derived gelsolin revealed several bands with a wide range of molecular weights: approximately 17 kDa to >188 kDa (Figure 2 columns A and B). Although the relative concentration for each band varied between immunoaffinity purified gelsolin from plasma and CSF, the banding pattern remained consistent suggesting processing of gelsolin in the plasma and CSF is similar. Western blot analysis of recombinant plasma gelsolin using mouse anti-hGSN showed a single band at 86 kDa, which corresponds to the full-length gelsolin molecule (Figure 2 column D). In comparison, Western blot of this same sample using goat anti-hGSN revealed multiple bands at 166 kDa, 86 kDa, 64 kDa, 60 kDa, 54 kDa, and 45 kDa (Figure 2 column C).

Eight bands were selected for tryptic digestion and identification by LC-ESI-MS/MS from the immunoaffinity purified plasma sample (Figure 2 column A). Gelsolin was found in each band; the peptides that were identified and their exact location in secreted pGSN are included in Table 1. The approximate molecular weight for each band as estimated by electrophoretic mobility is included. Furthermore, a theoretical minimum molecular weight for each band based on the peptides identified in that band and calculated using the ExPASy Compute pl/Mw tool was also included in Table 1. Some peptides were identified in almost every band, whereas several were identified in only one or two bands. Based on the identification by LC-ESI-MS/MS from the immunoaffinity purified plasma sample (Figure 2 column A), Gelso-
Table 1 LC/ESI-MS/MS identification of immunoaffinity purified forms of gelsolin

| Gel band | M.W.* | Theoretical minimum M.W. ** | Peptide sequence | Peptide position in pGSN |
|----------|-------|----------------------------|------------------|--------------------------|
| Band 1   | 86 kDa| 65816.00 kDa                | EVQGESATFLGYFK   | 121 - 135                |
|          |       |                            | HVVPNWVRQ        | 151 - 161                |
|          |       |                            | PAPGATEDTAKADAANR| 251 - 268                |
|          |       |                            | VQSVLEPGGETPLFK  | 347 - 363                |
|          |       |                            | PDPQDTGLGLSYLSSHIANVERV | 371 - 393         |
|          |       |                            | AQPQVQAESEPDGWEALGGKA | 600 - 621       |
|          |       |                            | DSQEEKEALTSRK    | 687 - 701                |
|          |       |                            | YETDPANR         | 702 - 711                |
|          |       |                            | RTPTVWK          | 714 - 721                |
| Band 2   | 83 kDa| 50126.19 kDa                | PALPAGTEDTAKE    | 251 - 262                |
|          |       |                            | QTQSVLEPGGETPLFK | 347 - 363                |
|          |       |                            | PDPQDTGLGLSYLSSHIANVERV | 371 - 393         |
|          |       |                            | AQPQVQAESEPDGWEALGGKA | 600 - 621       |
|          |       |                            | DSQEEKEALTSRK    | 687 - 701                |
|          |       |                            | YETDPANR         | 702 - 711                |
|          |       |                            | RTPTVW           | 714 - 721                |
| Band 3   | 64 kDa| 64805.80 kDa                | REVQGESATFLGYFKS | 120 - 136                |
|          |       |                            | KPAPGATEDTAKE    | 250 - 263                |
|          |       |                            | KQTQSVLEPGGETPLFKQ | 346 - 364           |
|          |       |                            | KDSEQEEKTEALTSRK | 686 - 702                |
|          |       |                            | RYETDPANRD       | 702 - 712                |
|          |       |                            | YETDPANR-        | 703 - 711                |
| Band 4   | 60 kDa| 49194.23 kDa                | KPAPGATEDTAKE    | 250 - 263                |
|          |       |                            | RDPQDTGLGLSYLSSHIANVERV | 370 - 393         |
|          |       |                            | KAGALSNDAVLKT    | 557 - 571                |
|          |       |                            | RAQPVQAESEPDGWEALGGKA | 599 - 622       |
|          |       |                            | KDSEQEEKTEALTSRK | 686 - 702                |
| Band 5   | 54 kDa| 41077.02 kDa                | KQTQSVLEPGGETPLFKQ | 346 - 364           |
|          |       |                            | RDPQDTGLGLSYLSSHIANVERV | 370 - 393         |
|          |       |                            | KPVPDPATYGQYGGDSYIILYNYRH | 430 - 455   |
|          |       |                            | KAGALSNDAVLKT    | 557 - 571                |
|          |       |                            | -TGAHELRL-      | 589 - 596                |
|          |       |                            | RAQPVQAESEPDGWEALGGKA | 599 - 622       |
|          |       |                            | KDSEQEEKTEALTSRK | 686 - 702                |
|          |       |                            | -RYETDPANR-      | 701 - 712                |
|          |       |                            | YETDPANRD        | 702 - 712                |
|          |       |                            | RTPTVWQK        | 713 - 722                |
| Band 6   | 45 kDa| 36044.42 kDa                | RVPDAAATLHTSTAAAACQHMDDDDGTGQKQ | 392 - 421          |
|          |       |                            | RVPDPAKTQYPQYGGDSYIILYNYRH | 430 - 455   |
|          |       |                            | KAGALSNDAVLKT    | 557 - 571                |
|          |       |                            | KTSAAYLWGTGASEAEKKT | 570 - 589            |
|          |       |                            | RAQPVQAESEPDGWEALGGKA | 599 - 622       |
|          |       |                            | KDSEQEEKTEALTSRK | 686 - 702                |
|          |       |                            | RYETDPANRD       | 702 - 712                |
|          |       |                            | RTPTVWQK        | 713 - 722                |
| Band 7   | 27 kDa| 30525.25 kDa                | VPVDPATYGQYGGDSYIILYNYR | 431 - 454          |
|          |       |                            | AGALSNDAVLKT    | 558 - 570                |
|          |       |                            | YETDPANR         | 702 - 711                |
| Band 8   | 19 kDa| 29308.93 kDa                | VPVDPATYGQYGGDSYIILYNYR | 431 - 454          |
|          |       |                            | DSQEEKEALTSRK    | 687 - 701                |

Included is the band identification (corresponding to extracted bands in Figure 1, column A), molecular weight based on electrophoretic mobility, theoretical minimum molecular weight as calculated using ExPASy Compute pI/Mw tool, identified peptides, and peptide location in secreted pGSN. The peptide -DSQEEEKTEALTSRK- was the most commonly identified peptide (in 7 of 8 bands). * - Molecular weight (M.W.) is approximate based on electrophoretic mobility in 1DE SDS-PAGE. ** - Theoretical Molecular weight was approximated using the ExPASy Compute pI/Mw tool and was calculated using the first peptide position through the last peptide position as determined using MS/MS.
fluids (including CSF) has been a daunting task. New biomarkers have not emerged as expected, despite the effort put forth experimentally by both small, single laboratories with limited clinical samples [3,13,27] as well as large, research organizations like the Human Plasma Proteome Project (HPPP) [28]. A conundrum has emerged with respect to validation of biomarkers following the discovery phase; is a lack of validation due to the assumptions that have been made about how a particular disease progresses or is it that the tools and reagents used are not adequate to the task? Accordingly, we postulate that a better understanding of the molecular mechanisms underlying diseases will help us to understand observed changes at the protein level and will also result in the validation of already discovered as well as new biomarker candidates.

For the majority of studies validation is based entirely or in part on immunoreactivity of specific antibodies. In terms of ELISA, this approach has been proven as very useful and accurate in many instances, e.g. measurement of bacterial proteins/toxins etc. However, when the dynamic changes of human proteins are measured or taken into consideration (including alternative splicing, post translational modification, regulated processing or degradation), immunoreactivity based assays become quite inaccurate. There has been and will continue to be attempts to improve these assays and thereby promote the acceptance of scientifically sound biomarkers. For example, Rifai et al. proposed a biomarker “pipeline” including discovery, qualification, verification, assay optimization, validation and commercialization to help aid in the discovery of better protein biomarkers [29].
Several of steps in this pipeline require the use of antibodies - from immunoaffinity purification in the qualification and verification stages to immunoassays like Western blot and ELISA in validation.

Experimental data that we present in this study helps to understand why in many cases validation based on immunoreactivity may lead to inconclusive or even misleading results. Moreover, we also conclude that other methods such as MRM may provide inaccurate results in the validation of biomarkers. For example, quantitative methods requiring the use of antibodies such as ELISA and quantitative Western blot will vary depending on which antibody is used (Figure 1 and Figure 2). Additionally, it was shown that the concentration of the biomarker in question might also adversely affect the results of quantitation using Western blot (Figure 3). With respect to quantitation, the different immunoaffinity purification methods used in sample preparation must also be considered. To date, our laboratory has yet to witness non-specific removal of gelsolin forms, however it has been realized that using different methods of immunoaffinity purification may adversely affect the quantitation of protein. Therefore using different methods of immunoaffinity purification should not be used in quantitative studies, but may be included in qualitative based studies. Furthermore, based on the results of this study, we reaffirmed that the conformation of the antigen does plays a key role for immunodetection; this was seen with the Western blots using mouse anti-hGSN antibody in Figures 1 and 2 being only able to detect a single gelsolin form. Additionally, goat anti-hGSN antibody was able to pull down various forms of gelsolin in human plasma during immunoaffinity purification; however it was unable to detect all the forms following 1DE, transfer and Western blot.

Our results reported here and those reported in previous papers [30-32] have a much broader implication to which method should be used for validation and eventually which potential biomarker candidate will be used or rejected from testing on larger cohorts of clinical samples.

Although ELISA has long been considered both reliable and high throughput and it is a technique that utilizes conjugated antibodies to quantify the targeted proteins, it also has limitations in its ability to differentiate between protein forms. In comparison, the Western blot - which is able to detect expression changes in the various forms of any given protein addressing the limitation of ELISA - is not a high-throughput technique and its reliability is often questioned because of saturation of chemiluminescent signal measured with X-ray films. Standardization of Western blot is much more difficult even if a fluorescently tagged secondary antibody is used. Protein microarrays, which address the issue of high-throughput, is also based on antigen-antibody interaction and must be performed using very well characterized antibodies. If an antibody used for microarrays recognizes only one or two forms, only a fragment of information about the differential expression of any protein will be received, similar to Western blot assay. Therefore, the 2D-differential in-gel electrophoresis (DIGE) profiling method - which separates full-length forms from fragments (resulting from processing or degradation) - appears to be an attractive alternative method. In our previous profiling studies using 2D-DIGE, we were able to show that the best indicator of changes of complement C3 in CSF, which is processed by multi-step well-defined mechanism, is a “residual” α-40 chain [18]. However, lack of good antibody to this fragment of C3 made orthogonal Western blot validation impossible at that time.

A novel approach known as Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) was developed to allow for the enrichment of targeted proteins in complex samples [33] and thereby could facilitate biomarker validation. This method is based on peptide quantitation in complex mixtures such as the total trypic digest of plasma samples. The SISCAPA method first combines immunoaffinity purified native peptide using anti-peptide antibodies immobilized on 100-nanoliter column and spiked stable-isotope-labeled internal standard peptide of the same sequence. Next, both peptides are measured by ESI-MS/MS and quantity is calculated based on the ratio of heavy (standard) to light (native) peptide, much like multiple reaction monitoring (MRM, below). Although the SISCAPA method may lead to increased sensitivity, it is a technology utilizing antibodies and therefore the same concerns with respect to ELISA and Western blot are applicable.

The MRM approach for validation is based on the comparison of abundance of selected peptides originating from a sample and spiked standard [16,34]; usually the peptides that are well ionized are selected for MRM quantitation. However, ambiguous results may occur depending on the peptide(s) chosen. For example, if one peptide is selected from N-terminal end of gelsolin and one from C-terminal region for MRM quantitation (or SISCAPA), the results of quantitative comparisons can be very different, as shown in Figure 5. More importantly, each peptide reflects a different situation; the N-terminal peptide will indicate quantity of full-length molecule and multimers whereas the C-terminal peptide will reflect the degree of gelsolin processing and/or degradation. Such an ambiguous result, if not further
explained, may result in the rejection of a putative biomarker from further studies. Additionally, if a third peptide from the mid-region is selected and the quantity is averaged, the end result may not be different than the control sample and potential biomarker will also be rejected from further studies.

Gelsolin is a candidate biomarker for several neurocognitive diseases but before it can be integrated into the “biomarker pipeline” [29], further steps must be made to improve the immunoreactivity of anti-gelsolin antibodies. Without further antibody development, characterization and optimization, candidate biomarkers such as gelsolin will lack quantitative validation and thereby be unable to enter clinical assay development.

Conclusions
Validation is one of the critical steps in bringing new biomarkers from bench to bedside in translational research. Our data presented here using gelsolin as an example, highlights a set of specific problems associated with antibody based validation methods. We also briefly describe how each of the current widely accepted methods of validation has inherent weaknesses yet each are strong enough that if used alone may lead to ambiguous or even false results. Hence, conclusions based on our experimental data have a broad application as to how we should approach validation methodologically and partially explains lack of real progress in the translation of biomarkers from bench to bedside.

Authors’ contributions
NH has performed the majority of the experimental work, wrote drafts of the manuscript and incorporated all suggested changes, has made drafts and final forms of all figures, and has made important contributions to the intellectual content. GP has made contributions to concept and design of the project, has been involved in revising the manuscript critically for important intellectual content, and has contributed to the designing of figures. JW has made substantial contributions to conception and design of the project, data analysis and interpretation, drafting of the manuscript, and has been involved in revising the manuscript critically for important intellectual content. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 2 September 2010 Accepted: 20 December 2010
Published: 20 December 2010
11. Tremblay RR, Coulombe E, Cloutier S, Brunet C, Deperthes D, Frenette G, Dube JY: Assessment of the trypsin-like human prostatic kallikrein, also known as hK2, in the seminal plasma of infertile men: respective contributions of an ELISA procedure and of Western blotting. J Lab Clin Med 1998, 131:330-335.

12. Imafuku Y, Ommen GS, Hanafu S: Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dia Markers 2004, 20:149-153.

13. Anderson L, Hunter CL: Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006, 5:573-589.

14. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA: Developing multiplexed assays for troponin I and targeted interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009, 55:1108-1117.

15. Kitteringham NR, Jenkins RE, Lane CS, Elliott VL, Park BK: Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:1229-1239.

16. Han B, Higgs RE: Proteomics: from hypothesis to quantitative assay on a single platform. Guidelines for developing MRM assays using ion trap mass spectrometers. Brief Funct Genomic Proteomic 2008, 7:340-354.

17. Rozek W, Homing J, Anderson J, Ciborowski P: Sera Proteomic Biomarker Profiling in HIV-1 Infected Subjects with Cognitive Impairment. Proteomics - Clinical Applications 2008, 2:1496-1507.

18. Rozek W, Ricardo-Dukelow M, Holloway S, Gendelman HE, Wojna V, Melendez LM, Ciborowski P: Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res 2007, 6:4189-4199.

19. Wiederin JL, Donahoe RM, Anderson JR, Yu F, Fox HS, Gendelman HE, Ciborowski PS: Plasma Proteomic Analysis of Simian Immunodeficiency Virus Infection of Rhesus Macaques. J Proteome Res 2010, 9:4721-4731.

20. Pottiez G, Haverland N, Ciborowski P: Mass spectrometric characterization of gelsolin isoforms. Rapid Commun Mass Spectrom 2010, 24:2620-2624.

21. Donahoe RM, O’Neill SP, Marsteller FA, Novembre FJ, Anderson DC, Lankford-Turner P, McClure HH: Probable deceleration of progression of Simian AIDS affected by opiate dependency: studies with a rhesus macaque/SIVsmm9 model. J Acquir Immune Defic Syndr 2009, 50:241-249.

22. Gendelman HE, Leonard JM, Dutko F, Kang S, Khilian J, Meltzer MS: Immunopathogenesis of human immunodeficiency virus infection in the central nervous system. Ann Neurol 1988, 23(Suppl):S78-81.

23. Ciborowski P, Kadlu J, Rozek W, Smith L, Bernardt JF, Fladsheth M, Ricardo-Dukelow M, Gendelman HE: Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology 2007, 363:198-209.

24. Ciborowski P, Enose Y, Mack A, Fladsheth M, Gendelman HE: Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. J Neuroimmunol 2004, 157:11-16.

25. Wiederin J, Rozek W, Duan F, Ciborowski P: Biomarkers of HIV-1 associated dementia: proteomic investigation of sera. Proteome Sci 2009, 7:8.

26. Lind SE, Jainey PA: Human plasma gelsolin binds to fibronectin. J Biol Chem 1984, 259:13262-13266.

27. Anderson NL: The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 56:177-185.

28. Ommen GS, States DJ, Adamiak M, Blackwell TW, Monen R, Hemjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, et al: Overview of the Human Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.

29. Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.

30. Rodriguez-Pineiro AM, Blanco-Preto S, Sanchez-Otero N, Rodriguez-Bernocal FJ, de la Cendra MP: On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics 73:1511-1522.

31. Lee PS, Bhan I, Thadani R: The potential role of plasma gelosin in diabetes-related protein-energy wasting. Blood Prod 29:99-101.

32. Ohnishi M, Matsumoto T, Nagashio R, Kageyama T, Utsuki S, Oka H, Okayasu I, Sato Y: Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelosin protein. Pathol Int 2009, 59:797-803.

33. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW: Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004, 3:235-244.

34. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, et al: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641.